DYRK1A and Dravet syndrome: While the leucettine derivative L41 was shown to prevent memory impairment produced by administration of the β-amyloid peptide Aβ25–35 in rodents31, to the best of our knowledge, none of the current competitive DYRK1A inhibitors has passed the in vitro stage of investigation with respect to improvement of cognitive impairments in DS.